Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
일요일, 8월 30

Artiva Biotherapeutics Inc

ARTVNASDAQ
Trade with Public
Trade with Public
$11.09
-0.85-7.12%
가까이에: Aug 28, 5:00 PM EST
$11.14
0.050.45%
시간외: Aug 28, 6:48 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Artiva Biotherapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Artiva Biotherapeutics (ARTV).

Price Target Range — 7 Quarters

Analyst Consensus — 6 Analysts

6Buy
Consensus RatingBuy# Analysts6Avg. Consensus PT$31Upside to Avg. PT+175.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 8, 2026NeedhamGil BlumMaintainedBuy$41
May 12, 2026NeedhamGil BlumPT RaiseBuy$18→$41
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $41 Price Target

Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains $41 price target.
Benzinga Newsdesk

PRO
Needham Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $41

Needham analyst Gil Blum maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and raises the price target from $18 to $41.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on Artiva Biotherapeutics, Raises Price Target to $40

Cantor Fitzgerald analyst Josh Schimmer maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Overweight and raises the price target from $10 to $40.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Artiva Biotherapeutics, Raises Price Target to $40

Wedbush analyst Martin Fan maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Outperform and raises the price target from $23 to $40.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $35

HC Wainwright & Co. analyst Emily Bodnar maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and raises the price target from $15 to $35.
Benzinga Newsdesk

PRO
Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $18 Price Target

Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains $18 price target.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved